| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Geoffrey Russell, Samuel Reinfeld, Olivia Kam, Gloria Lee, Melissa Weiss, Maju Mathew Kool. Case series on aripiprazole and dopamine supersensitivity psychosis. International clinical psychopharmacology. 2022-02-10. PMID:35143441. |
diagnosis of schizophrenia experienced severe worsening of psychosis within 4-5 days of abrupt switching to aripiprazole from a full d2 antagonist. |
2022-02-10 |
2023-08-13 |
Not clear |
| Zhe Lu, Yuyanan Zhang, Hao Yan, Yi Su, Liangkun Guo, Yundan Liao, Tianlan Lu, Hao Yu, Lifang Wang, Jun Li, Wenqiang Li, Yongfeng Yang, Xiao Xiao, Luxian Lv, Yunlong Tan, Dai Zhang, Weihua Yu. ATAD3B and SKIL polymorphisms associated with antipsychotic-induced QTc interval change in patients with schizophrenia: a genome-wide association study. Translational psychiatry. vol 12. issue 1. 2022-02-09. PMID:35136033. |
a total of 2040 patients with schizophrenia were randomly assigned to six groups (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and first-generation antipsychotics; first-generation antipsychotics including haloperidol or perphenazine were also assigned randomly) and received 6-week antipsychotic treatment. |
2022-02-09 |
2023-08-13 |
Not clear |
| Chia-Hao Ma, Hung-Yu Chan, Ming H Hsieh, Chen-Chung Liu, Chih-Min Liu, Hai-Gwo Hwu, Ching-Hua Kuo, Wei J Chen, Tzung-Jeng Hwan. Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia. Therapeutic advances in psychopharmacology. vol 12. 2022-02-03. PMID:35111295. |
identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia. |
2022-02-03 |
2023-08-13 |
Not clear |
| Renata Cristina Mendes Ferreira, Douglas Lamounier de Almeida, Igor Dimitri Gama Duarte, Daniele Cristina Aguiar, Fabrício Araújo Moreira, Thiago Roberto Lima Romer. The antipsychotic aripiprazole induces peripheral antinociceptive effects through PI3Kγ/NO/cGMP/K European journal of pain (London, England). 2022-01-19. PMID:35044019. |
the antipsychotic aripiprazole induces peripheral antinociceptive effects through pi3kγ/no/cgmp/k aripiprazole is an antipsychotic drug used to treat schizophrenia and bipolar disorder. |
2022-01-19 |
2023-08-13 |
Not clear |
| Adam Wichniak, Jerzy Samochowiec, Agata Szulc, Dominika Dudek, Janusz Heitzman, Małgorzata Janas-Kozik, Tomasz Wolańczyk, Joanna Rymaszewska, Marcin Siwek, Przemysław Bieńkowsk. The position statement of the Working Group of the Polish Psychiatric Association on the use of D2/D3 dopamine receptor partial agonists in the treatment of mental disorders. Psychiatria polska. vol 55. issue 5. 2022-01-08. PMID:34997736. |
this is the reason for the increasing use of these drugs in the treatment of schizophrenia and mood disorders, and in the case of aripiprazole also in obsessive-compulsive, autism-spectrum and tic disorders. |
2022-01-08 |
2023-08-13 |
Not clear |
| Le Xiao, Qian Zhao, An-Ning Li, Jushui Sun, Bin Wu, Lina Wang, Honggeng Zhang, Ruiling Zhang, Keqing Li, Xiaojin Xu, Tiebang Liu, Wenshun Zhang, Shiping Xie, Xiufeng Xu, Yunlong Tan, Kerang Zhang, Hongyan Zhang, Nianhong Guan, Mingji Xian, Motomichi Uki, Gang Wan. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study. Psychopharmacology. 2022-01-06. PMID:34989824. |
efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study. |
2022-01-06 |
2023-08-13 |
Not clear |
| Le Xiao, Qian Zhao, An-Ning Li, Jushui Sun, Bin Wu, Lina Wang, Honggeng Zhang, Ruiling Zhang, Keqing Li, Xiaojin Xu, Tiebang Liu, Wenshun Zhang, Shiping Xie, Xiufeng Xu, Yunlong Tan, Kerang Zhang, Hongyan Zhang, Nianhong Guan, Mingji Xian, Motomichi Uki, Gang Wan. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study. Psychopharmacology. 2022-01-06. PMID:34989824. |
the present study aimed to evaluate the efficacy and safety of aripiprazole once-monthly (aom) compared to oral aripiprazole in treating acute schizophrenia. |
2022-01-06 |
2023-08-13 |
Not clear |
| Xiaofeng Wang, Arash Raoufinia, Sébastien Bihorel, Julie Passarell, Suresh Mallikaarjun, Luann Phillip. Population Pharmacokinetic Modeling and Exposure-Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia. Clinical pharmacology in drug development. 2022-01-03. PMID:34979059. |
population pharmacokinetic modeling and exposure-response analysis for aripiprazole once monthly in subjects with schizophrenia. |
2022-01-03 |
2023-08-13 |
human |
| Juan J Fernández-Miranda, Silvia Díaz-Fernández, Francisco López-Muño. Adherence, Tolerability and Effective Doses of Aripiprazole Once-monthly in the Long-term Treatment of Patients with Severe Schizophrenia. Current pharmaceutical design. vol 27. issue 39. 2021-12-07. PMID:34218772. |
adherence, tolerability and effective doses of aripiprazole once-monthly in the long-term treatment of patients with severe schizophrenia. |
2021-12-07 |
2023-08-13 |
Not clear |
| Chih-Sung Liang, Tung-Ping Su, Ming-Hsien Hsieh, Chau-Shoun Lee, Joseph Kuo, Nan-Ying Chiu, Po-See Chen, Yung-Chieh Yen, Ya-Mei Ba. Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia. Journal of personalized medicine. vol 11. issue 11. 2021-11-30. PMID:34834550. |
taiwan expert consensus recommendations for switching to aripiprazole long-acting once-monthly in patients with schizophrenia. |
2021-11-30 |
2023-08-13 |
Not clear |
| Chih-Sung Liang, Tung-Ping Su, Ming-Hsien Hsieh, Chau-Shoun Lee, Joseph Kuo, Nan-Ying Chiu, Po-See Chen, Yung-Chieh Yen, Ya-Mei Ba. Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia. Journal of personalized medicine. vol 11. issue 11. 2021-11-30. PMID:34834550. |
aripiprazole long-acting once-monthly (aom) is the only long-acting dopamine partial agonist antipsychotic approved for schizophrenia; however, a literature search revealed no guidance on safely switching from oral and long-acting injectable antipsychotics to aom. |
2021-11-30 |
2023-08-13 |
Not clear |
| V Yu Skryabin, M A Vinnikova, E V Ezhkova, M S Titkov, R A Bulatov. Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study. Journal of addictive diseases. vol 39. issue 4. 2021-11-29. PMID:33832406. |
the article presents the results of a randomized comparative study of aripiprazole and quetiapine in the treatment of patients with a dual diagnosis: schizophrenia and substance use disorders. |
2021-11-29 |
2023-08-13 |
Not clear |
| José Manuel Olivares, Ana González-Pinto, Mario Páram. Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study. European psychiatry : the journal of the Association of European Psychiatrists. vol 64. issue 1. 2021-11-19. PMID:33840396. |
predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the spanish clinical practice: a retrospective, observational study. |
2021-11-19 |
2023-08-13 |
Not clear |
| José Manuel Olivares, Ana González-Pinto, Mario Páram. Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study - CORRIGENDUM. European psychiatry : the journal of the Association of European Psychiatrists. vol 64. issue 1. 2021-11-18. PMID:34632976. |
predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the spanish clinical practice: a retrospective, observational study - corrigendum. |
2021-11-18 |
2023-08-13 |
Not clear |
| Minami Tasaki, Norio Yasui-Furukori, Kazuyoshi Kubo, Saaya Yokoyama, Masataka Shinozaki, Norio Sugawara, Yoshimasa Inoue, Kazutaka Shimod. Relationship of Prolactin Concentrations to Steady-State Plasma Concentrations of Aripiprazole in Patients With Schizophrenia. Therapeutic drug monitoring. vol 43. issue 4. 2021-11-17. PMID:33235024. |
relationship of prolactin concentrations to steady-state plasma concentrations of aripiprazole in patients with schizophrenia. |
2021-11-17 |
2023-08-13 |
Not clear |
| Jun Ishigooka, Kazuyuki Nakagome, Tetsuro Ohmori, Nakao Iwata, Ken Inada, Jun-Ichi Iga, Taro Kishi, Kiyoshi Fujita, Yuka Kikuchi, Toshiaki Shichijo, Hideaki Tabuse, Shotatsu Koretsune, Hiroshi Terada, Haruko Terada, Toshifumi Kishimoto, Yuichiro Tsutsumi, Yoshiki Kanda, Kazutaka Ohi, Kanji Sekiyam. Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study. Psychiatry and clinical neurosciences. 2021-11-17. PMID:34626144. |
the japan useful medication program for schizophrenia (jumps) is a large-scale, long-term naturalistic study to present pivotal 52-week data on the continuity of second-generation antipsychotics (sga: aripiprazole, blonanserin, and paliperidone). |
2021-11-17 |
2023-08-13 |
Not clear |
| Mirjam Wolfschlag, Anders Håkansso. Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden. PloS one. vol 16. issue 6. 2021-11-12. PMID:34061895. |
a similar association was found between aripiprazole prescriptions and gd diagnoses, which were analysed within the subgroup of all patients with schizophrenia or a schizotypal, delusional, or another non-mood psychotic disorder. |
2021-11-12 |
2023-08-13 |
Not clear |
| Yanlin Wang, Xiaofeng Wang, Matt Harlin, Frank Larsen, Moeen Panni, Murat Yildirim, Jessica Madera, Liz Arias, Andy Forbes, Nihal Mustafa, Inez Ruiz-White, Arash Raoufini. An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. Current medical research and opinion. vol 37. issue 11. 2021-11-12. PMID:34407720. |
an alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. |
2021-11-12 |
2023-08-13 |
Not clear |
| Yanlin Wang, Xiaofeng Wang, Matt Harlin, Frank Larsen, Moeen Panni, Murat Yildirim, Jessica Madera, Liz Arias, Andy Forbes, Nihal Mustafa, Inez Ruiz-White, Arash Raoufini. An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. Current medical research and opinion. vol 37. issue 11. 2021-11-12. PMID:34407720. |
the single-injection start regimen for aripiprazole once-monthly 400 mg (aom 400) in patients with schizophrenia requires a single intramuscular injection in the gluteal or deltoid site and 14 days of concurrent oral therapy. |
2021-11-12 |
2023-08-13 |
Not clear |
| John Wang, Kamber L Hart, Wei Qi, Babak A Ardekani, Chenxiang Li, Julia Marx, Oliver Freudenreich, Corinne Cather, Daphne Holt, Iruma Bello, Erica D Diminich, Yingying Tang, Michelle Worthington, Botao Zeng, Renrong Wu, Xiaoduo Fan, Jingping Zhao, Jijun Wang, Donald C Gof. Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia. Journal of clinical psychopharmacology. vol 41. issue 3. 2021-11-09. PMID:33814546. |
association of aripiprazole with reduced hippocampal atrophy during maintenance treatment of first-episode schizophrenia. |
2021-11-09 |
2023-08-13 |
Not clear |